drugset / Trial / NCT01365637

The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.

NCT01365637

Phase 1 Completed 30 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is primarily to determine the safety and toleration and pharmacokinetics of PF-05089771 following escalating multiple doses lasting for 14 days. Dosing will either be administered twice or three times daily. Secondary objectives will be to investigate the PK of an alternative formulation of PF-05089771 and the effect of food on the PK of PF-05089771.

Timeline

Start
2011-06
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05089771 Small molecule

Indications

No indication recorded.